Discovery and Development of Small Molecule Drugs to Enhance Patient Lives
Welcome to Rigel
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases.
About TAVALISSE®
TAVALISSE (fostamatinib disodium hexahydrate) tablets are indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Our Pipeline
Rigel has a robust and growing pipeline of investigational products focused on treating disease by modulating the immune system.
Clinical Trials
Rigel is enrolling a Phase 3 clinical study of an investigational drug for warm antibody Autoimmune Hemolytic Anemia (AIHA).